Collectively, our in vivo data demonstrated that shikonin treatment results in a durable therapeutic response and can be an effective treatment in preselected SDHA- and LRPPRC-overexpressing ovarian tumors, which introduces hope for improving current therapies for ovarian cancer patients. Here, SDHA is linked to ovarian neoplasm.